Literature DB >> 34213641

Risk prediction models based on hematological/body parameters for chemotherapy-induced adverse effects in Chinese colorectal cancer patients.

Mingming Li1, Jiani Chen1,2, Yi Deng1, Tao Yan3, Haixia Gu2, Yanjun Zhou2, Houshan Yao4, Hua Wei5,6, Wansheng Chen7,8.   

Abstract

PURPOSE: To determine risk factors and develop novel prediction models for chemotherapy-induced adverse effects (CIAEs) in Chinese colorectal cancer (CRC) patients receiving capecitabine.
METHODS: A total of 233 Chinese CRC patients receiving post-operative chemotherapy with capecitabine were randomly divided into a training set (70%) and a validation set (30%). CIAE-related hematological/body parameters were screened by univariate logistic regression. Based on a set of factors selected from LASSO (least absolute shrinkage and selection operator) logistic regression, stepwise multivariate logistic regression was applied to develop prediction models. Area under the receiver operating characteristic (ROC) curve and Hosmer-Lemeshow (HL) test were used to evaluate the discriminatory ability and the goodness of fit of each model.
RESULTS: In total, 35 variables were identified to be associated with CIAEs in univariate analysis. Developed multivariable models had AUCs (area under curve) ranging from 0.625 to 0.888 and 0.428 to 0.760 in the training and validation set, respectively. The grade ≥ 1 anemia multivariable model achieved the best discriminatory ability with AUC of 0.760 (95%CI: 0.609-0.912) and good calibration with HL P value of 0.450. Then, a nomogram was constructed to predict grade ≥ 1 anemia, which included variables of age, pre-operative hemoglobin count, and pre-operative albumin count, with C-indexes of 0.775 and 0.806 in the training and validation set, respectively.
CONCLUSIONS: This study identified valuable hematological/body parameters related to CIAEs. A nomogram based on the multivariable model including three hematological/body predictors can accurately predict grade ≥ 1 anemia, facilitating clinicians to implement personalized medicine early for Chinese CRC patients receiving post-operative chemotherapy for better safety treatment. Trial registration This study was registered as a clinical trial at www.clinicaltrials.gov (NCT03030508).

Entities:  

Keywords:  Anemia; Bone marrow suppression; Capecitabine; Chemotherapy-induced adverse effects; Chemotherapy-induced nausea and vomiting; Colorectal cancer; Hematological/body parameters; Prediction model

Year:  2021        PMID: 34213641     DOI: 10.1007/s00520-021-06337-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  47 in total

1.  Chemotherapy combined with target drugs in the treatment of advanced colorectal cancer: a meta-analysis based on Chinese patients.

Authors:  Q H Zheng; X L Wu; X L Che; M L Weng; J X Chen; Y Zou
Journal:  Indian J Cancer       Date:  2014-03       Impact factor: 1.224

2.  Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer.

Authors:  Stephen L Chan; Anthony W H Chan; Frankie Mo; Brigette B Y Ma; Kenneth C W Wong; Daisy Lam; Florence S T Mok; Anthony T C Chan; Tony Mok; K C Allen Chan
Journal:  Oncologist       Date:  2018-05-25

3.  A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.

Authors:  Marc Ychou; Michel Rivoire; Simon Thezenas; François Quenet; Jean-Robert Delpero; Christine Rebischung; Christian Letoublon; Rosine Guimbaud; Eric Francois; Michel Ducreux; Françoise Desseigne; Jean-Michel Fabre; Eric Assenat
Journal:  Ann Surg Oncol       Date:  2013-08-17       Impact factor: 5.344

4.  Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.

Authors:  Ralf-Dieter Hofheinz; Deniz Gencer; Holger Schulz; Michael Stahl; Susanna Hegewisch-Becker; Luisa Mantovani Loeffler; Ursula Kronawitter; Georg Bolz; Jochem Potenberg; Felix Tauchert; Salah-Eddin Al-Batran; Andreas Schneeweiss
Journal:  J Clin Oncol       Date:  2015-06-29       Impact factor: 44.544

5.  [A case of Stage IV sigmoid colon cancer that achieved long-term survival with oral anticancer drugs].

Authors:  Yako Hasegawa; Hideyuki Iwata; Masayuki Hatanaka
Journal:  Gan To Kagaku Ryoho       Date:  2014-03

6.  Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy.

Authors:  Neil B Newman; Manpreet K Sidhu; Rekha Baby; Rebecca A Moss; Michael J Nissenblatt; Ting Chen; Shou-En Lu; Salma K Jabbour
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-01-05       Impact factor: 7.038

7.  NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

Authors:  Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Lynette Cederquist; Yi-Jen Chen; Kristen K Ciombor; Stacey Cohen; Harry S Cooper; Dustin Deming; Paul F Engstrom; Ignacio Garrido-Laguna; Jean L Grem; Axel Grothey; Howard S Hochster; Sarah Hoffe; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Eric D Miller; Mary F Mulcahy; James D Murphy; Steven Nurkin; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Evan Wuthrick; Kristina M Gregory; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2018-04       Impact factor: 11.908

8.  Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.

Authors:  Yoon-Sim Yap; Li-Lian Kwok; Nicholas Syn; Wen Yee Chay; John Whay Kuang Chia; Chee Kian Tham; Nan Soon Wong; Soo Kien Lo; Rebecca Alexandra Dent; Sili Tan; Zuan Yu Mok; King Xin Koh; Han Chong Toh; Wen Hsin Koo; Marie Loh; Raymond Chee Hui Ng; Su Pin Choo; Richie Chuan Teck Soong
Journal:  JAMA Oncol       Date:  2017-11-01       Impact factor: 31.777

9.  Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.

Authors:  Xandra García-González; Lucía Cortejoso; María I García; Pilar García-Alfonso; Luis Robles; Cristina Grávalos; Eva González-Haba; Pellicer Marta; María Sanjurjo; Luis A López-Fernández
Journal:  Oncotarget       Date:  2015-03-20

10.  Patients' self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis.

Authors:  Kazuyoshi Kawakami; Eri Nakamoto; Takashi Yokokawa; Kazuo Sugita; Yutarou Mae; Akane Hagino; Mitsukuni Suenaga; Nobuyuki Mizunuma; Sayaka Oniyama; Yoshiaki Machida; Toshiharu Yamaguchi; Toshihiro Hama
Journal:  Patient Prefer Adherence       Date:  2015-04-09       Impact factor: 2.711

View more
  2 in total

1.  Milk and Egg Are Risk Factors for Adverse Effects of Capecitabine-Based Chemotherapy in Chinese Colorectal Cancer Patients.

Authors:  Jinrong Xu; Zeshuai Lin; Jiani Chen; Jian Zhang; Wanqing Li; Rui Zhang; Jin Xing; Zhihuan Ye; Xiaoping Liu; Qianmin Gao; Xintao Chen; Jingwen Zhai; Houshan Yao; Mingming Li; Hua Wei
Journal:  Integr Cancer Ther       Date:  2022 Jan-Dec       Impact factor: 3.077

Review 2.  A Systematic Review of Clinical Validated and Potential miRNA Markers Related to the Efficacy of Fluoropyrimidine Drugs.

Authors:  Xiaomeng Sun; Jiani Chen; Xintao Chen; Qianmin Gao; Wei Chen; Xun Zou; Feng Zhang; Shouhong Gao; Shi Qiu; Xiaoqiang Yue; Houshan Yao; Xuan Liu; Mingming Li
Journal:  Dis Markers       Date:  2022-08-23       Impact factor: 3.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.